Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 12/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7074009 | 0.88 | NR3C1 (0.48) | SPRPOLBCCR2CCR5NR3C1 | |
| SCHEMBL7079006 | 0.87 | MEN1 (0.45) | SPRPOLBCCR2CCR5NR3C1 | |
| SCHEMBL5961427 | 0.86 | CCR2 (0.51) | SPRPOLBCCR2CCR5NR3C1 | |
| SCHEMBL5961577 | 0.85 | CCR2 (0.51) | CCR2CCR5NR3C1SMN1; SMN2 | |
| SCHEMBL7079264 | 0.84 | NR3C1 (0.40) | SPRPOLBCCR2CCR5NR3C1 | |
| SCHEMBL7077952 | 0.84 | SPR (0.48) | SPRPOLBCCR2CCR5NR3C1 | |
| SCHEMBL5961510 | 0.84 | PTK6 (0.42) | SPRPOLBCCR2CCR5NR3C1 | |
| SCHEMBL7078063 | 0.83 | SPR (0.40) | SPRPOLBCCR2CCR5NR3C1 | |
| SCHEMBL5961540 | 0.82 | LCK (0.42) | NR3C1RAB9ASMN1; SMN2 | |
| SCHEMBL5961522 | 0.82 | CCR2 (0.53) | SPRPOLBCCR2CCR5NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6670364-B2 | For example (1,3-dimethylpyrazolo(5,4-b)pyridin-5-yl)-N-(((4-fluorophenyl) amino)carbonyl)-carboxamide; useful in prevention or treatment of chronic or acute inflammatory or autoimmune diseases | TELIK, INC. | 2003-12-30 | — | — | US | claimed |
| US-20030096705-A1 | Antagonists of MCP-1 function and methods of use thereof | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2003-05-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096705-A1 | Antagonists of MCP-1 function and methods of use thereof | CCR2, CCR1, CCL2 | SPR 430/4885POLB 3248/4885CCR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.